The Epilepsy-aphasia spectrum (EAS) is a spectrum of disorders from severe epileptic encephalopathy with continuous spike-waves in sleep (ECSWS) and LandauKleffner syndrome (LKS) to the mild condition of childhood epilepsy with centrotemporal spikes. Some of the disorders show a male bias, and there is evidence to suggest a genetic cause. 1 The N-methyl-D-aspartate (NMDA) subunit encoded by GRIN2A was the first gene associated with EAS. [2] [3] [4] [5] Recently, the Ras-signaling protein encoded by CNKSR2 (connector enhancer of KSR2), [6] [7] [8] [9] [10] was shown to cause phenotypes within the EAS spectrum; four of five unrelated probands had CNKSR2 deletions discovered using chromosomal microarrays, suggesting loss of the protein at brain synapses to be pathogenic. 6, 7, 10 However, no study has systematically determined the contribution of CNKSR2 point mutations to the EAS.
Materials and Methods

Subjects
We searched for DNA variation in CNKSR2 among our cohort of 112 EAS probands (62 male, 50 female) where there was no evidence of male-to-male transmission. There were 50 familial cases and 62 sporadics. The breakdown of phenotypes of this cohort is shown in Table 1 . Genomic DNA was extracted from venous blood with standard methods. 11 A subset of the cohort has received testing for other genes associated with aphasia such as GRIN2A, for which they were negative. No individuals in the reported pedigree have had other genes sequenced using either a gene panel or by whole exome analysis. The Human Research Ethics Committee (project No. H2007/02961) of Austin Health, Melbourne, Australia, and the Wolfson Medical Centre Institutional Review Board approved this study. Written informed consent was obtained from all subjects or their parents or legal guardians.
PCR and sequencing
Coding exons and splice sites of the CNKSR2 gene were polymerase chain reaction (PCR) amplified using specific primers designed to all isoforms using reference human gene transcripts (NCBI Gene; http://www.ncbi.nlm.nih. gov/). Primer sequences are available upon request. Amplification reactions were cycled using a standard protocol on a Veriti Thermal Cycler (Applied Biosystems, Carlsbad, CA, U.S.A.). Bidirectional sequencing of all exons and flanking intronic regions including splice sites was completed with a BigDye v3.1 Terminator Cycle Sequencing Kit (Applied Biosystems), according to the manufacturer's instructions. Sequencing products were resolved using a 3730xl DNA Analyzer (Applied Biosystems). All sequencing chromatograms were compared to published complementary DNA (cDNA) sequence; nucleotide changes were detected using Codon Code Aligner (CodonCode Corporation, Dedham, MA, U.S.A.).
Results
Genetic analysis
We detected a novel nonsense mutation (c.2314 C>T; p.Arg712*) in the proband from one Ashkenazi Jewish family ( Fig. 1 ) that is not present in available public databases including the Exome Aggregation Consortium (ExAC), Exome Variant Server or 1000 Genomes. Although a variant (p.Arg712Gln) is reported on ExAC to affect the same residue, this variant is not relevant because it is a missense change present in control individuals, whereas we have found a novel nonsense mutation at the same residue. Segregation analysis revealed that the mutation was present in all three affected siblings and was inherited in an X-linked manner from their mother who had febrile seizures. Samples from the mother's siblings, including the affected uncle, were unavailable for genetic analysis.
The p.Arg712* mutation is located toward the C-terminal of the protein and is predicted to result in a truncated protein lacking the last 322 of 1,034 residues. This portion of the protein includes a coiled-coil functional domain (residues 875-904; http://www.uniprot.org/uniprot/Q8WXI2). The p.Arg712 residue is also located only six residues away Frequency of CNKSR2 Mutation from a known short proline-rich motif (PPPP P2; residues 703-706) that has been shown to be essential for binding of CNKSR2 to WW domains of Vilse, 12 a protein previously reported to interact with the axon guidance receptor Robo1. 13 Disruption of this interaction may adversely affect synaptic activity. The other possibility is complete loss of the protein due to nonsense-mediated decay (NMD). We were unable to test for NMD because we could not obtain fresh blood samples from affected family members. All reported deletion or frameshift CNKSR2 mutations in EAS patients either include or are predicted to lead to loss of the C-terminal portion of the protein where our nonsense mutation is located.
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Phenotypic analysis
In the proband, seizures began at 3.5 years with developmental and language delay occurring prior to seizure onset. Sleep-electroencephalography (EEG) demonstrated continuous bilateral centrotemporal or frontal spike and wave activity. Comorbidities included attention deficits and hyperactivity. At 4 years, the probands behavior, cognition, and language deteriorated, and he became aphasic. At 12 years he was institutionalized with neuropsychiatric deterioration and remains institutionalized at age 18 years.
The proband's brother also had seizures onset at 3.5 years with developmental and language delay prior to seizure onset, continuous bilateral centrotemporal or frontal spike and wave activity on sleep-EEG (Fig. 2) , and attention deficit and hyperactivity. At age 12 years he was less severely affected than the proband, as indicated by useful language and attendance at regular school. However, he requires ongoing antiepileptic medication.
Their sister had mild motor and language delay and seizure onset at 6 years; left centrotemporal spikes were recorded on EEG, consistent with a diagnosis of childhood epilepsy with centrotemporal spikes. At age 16 years, she was seizure free without medication and had mild learning difficulties.
The sibling's mother had febrile seizures without language or intellectual impairment. Their maternal uncle (DNA unavailable) had refractory seizures from 3.5 years Figure 2 . Centrotemporal or frontal spike and wave activity on sleep-EEG. EEG from the proband's brother at 10.5 years showing continuous right-sided focal epileptiform activity, maximum in the temporal region with some involvement on the left. Epilepsia ILAE of age; he had ECSWS recorded on sleep-EEG and had a language and motor delay. His seizures responded to the ketogenic diet, and by 5 years of age his EEG had normalized and the diet was discontinued. He had rare seizures over a few years, and by 10 years he had ceased all medication. He has autism and mild-to-moderate intellectual disability.
Discussion
We confirm recent studies [6] [7] [8] [9] [10] reporting CNKSR2 mutations in patients with the EAS spectrum and show that the frequency is low (1/112) . Although large deletions have been reported, 6,7,11 they are not likely to be present in our screening cohort, since we amplified CNKSR2 exonic DNA from all probands by PCR.
In our family, all affected males had onset of seizures at 3.5 years comparable to 2 or 2.5 years for four reported male cases but older than 8 days or neonatal onset in an additional two male cases. 6, 10 Frequent or continuous spike and wave patterns on EEG has been documented in six reported cases, consistent with the three affected males from our family. 6, 9, 10 Most of reported patients, including our family, have severe speech delay, often commencing prior to the time of seizure onset, which may continue and result in lifelong language loss. 10 Developmental and psychomotor delay are common features (again prior to seizures onset), as is intellectual disability. 6, 8 Finally, behavioral disturbances including severe attention deficit and hyperactivity have been frequently observed here and elsewhere. 10 The previously reported cases of CNKSR2 deficiency causing seizures have all been male, with their genotype being inherited from unaffected carrier mothers. Herein we report the first female with EAS and a CNKSR2 mutation. The sister, in our family, has a less severe phenotype than her two brothers have; this could be because the females are heterozygous and likely subject to X-inactivation, although the latter was not measured. Of interest, the mother, who also carries the point mutation, had only febrile seizures. Both febrile seizures and benign childhood epilepsy with centrotemporal spikes (BECTS) are common seizure disorders, with the former affecting~3% of children in the Western European population, whereas the latter accounts for~10% of focal epilepsies in children. ECSWS is much rarer, although it has been associated with CNKSR2 mutation in several unrelated cases. [6] [7] [8] [9] [10] This is the first report of BECTS and febrile seizures in female patients carrying a CNKSR2 mutation.
Our data suggest in cases with suspected X-linked EASspecifically in males with ECSWS, developmental delay, affected speech, and early onset seizures-that CNKSR2 gene sequencing should be performed in addition to standard clinical microarrays for detection of large deletions at the CNKSR2 locus. Examinations of regulatory regions outside the coding and splice-site regions interrogated here are an area for future research. Finding a pathogenic mutation in CNKSR2 will help clinicians with diagnosis and genetic counseling, with implications for expressivity of both severe (e.g., ECSWS), and milder (e.g. BECTS and FS), phenotypes, depending on whether the mutation is inherited by male or female offspring.
